HEPLISAV-B Product Info 

Learn more about HEPLISAV-B, the only 2-dose-in-1-month adult hepatitis B vaccine approved for use in the United States!1

HEPLISAV-B Formulary Announcement
Download and share formulary information with your team so they can order HEPLISAV-B today.

EHR, electronic health record.


  1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 

Important Safety Information


HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 


Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). 

Please see full Prescribing Information.